The Readout

By  Damian Garde

Your guide to what’s new in biotech. Sign up for the newsletter here.

The READOUT
The Readout

Pharma’s future in China & Parker’s first biotech startup

By Damian Garde

The READOUT
The Readout

PhRMA takes on Pelosi & a costly pancreatic cancer failure

By Damian Garde

The READOUT
The Readout

Gene therapy’s slump & Gilead’s new CFO

By Damian Garde

The READOUT
The Readout

An alarming IPO stat & Ancestry rolls out health tests

By Damian Garde

The READOUT
The Readout

Unicorns, more unicorns, & cancer pricing economics

By Meghana Keshavan

The READOUT
The Readout

PhRMA’s geographic omission & Alexion gets a rival

By Meghana Keshavan

The READOUT
The Readout

23andMe and secrecy & a discordant price hike

By Damian Garde

The READOUT
The Readout

The debate over Regeneron’s fate & your guide to biotech VC

By Damian Garde

The READOUT
The Readout

A biotech disinformation campaign & an FDA controversy

By Damian Garde

The READOUT
The Readout

Buttigieg’s radical pricing plan & good news from Sarepta

By Meghana Keshavan

The READOUT
The Readout

Microbial dark matter & a mixed bag of IPOs

By Meghana Keshavan

The READOUT
The Readout

Sarepta’s latest headache & a big day for IPOs

By Damian Garde

The READOUT
The Readout

Biogen’s confidence issue & biotech’s slumping fortunes

By Damian Garde

The READOUT
The Readout

Biotech’s big catalysts & the latest on congressional insider trading

By Damian Garde

The READOUT
The Readout

News from ESMO & an FTC slow dance with Allergan and AbbVie

By Meghana Keshavan

The READOUT
The Readout

A big add to the NYC biotech scene & an FDA warning

By Meghana Keshavan

The READOUT
The Readout

23andMe does clinical trial recruitment & drug pricing realpolitik

By Damian Garde

The READOUT
The Readout

A global CRISPR want ad & AveXis’ messy breakup

By Damian Garde

The READOUT
The Readout

FAANG turns to DNA & a C-suite clear-out

By Damian Garde

The READOUT
The Readout

A major diabetes approval & a shiny new incubator

By Damian Garde

The READOUT
The Readout

New microbiomes for transplant & new data on Zolgensma

By Meghana Keshavan

The READOUT
The Readout

Fighting cancer’s back-up plan & Ginkgo’s eyebrow-raising valuation

By Damian Garde

The READOUT
The Readout

Shkreli’s financial health & Dr. Oz gets into biotech

By Damian Garde

The READOUT
The Readout

Nonprofits are VCs now & Biogen’s latest stumble

By Damian Garde

The READOUT
The Readout

Pelosi’s pricing plan & CRISPR’ing to save a sibling

By Meghana Keshavan

The READOUT
The Readout

Nocion gets hit with a lawsuit & Aimmune’s adcom gets underway

By Adam Feuerstein

The READOUT
The Readout

Moderna’s shiny new data & pharma conceals evidence

By Meghana Keshavan

The READOUT
The Readout

A lesson on Gardasil & a reveal on liquid biopsy data

By Kate Sheridan

The READOUT
The Readout

A savvy contender to lead the FDA & the non-drug Alzheimer’s pipeline

By Rebecca Robbins

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy